Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties

Abstract Computational pharmacogenomics can potentially identify new indications for already approved drugs and pinpoint compounds with similar mechanism-of-action. Here, we used an integrated drug repositioning approach based on transcriptomics data and structure-based virtual screening to identify...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Peter Larsson, Maria Cristina De Rosa, Benedetta Righino, Maxim Olsson, Bogdan Iulius Florea, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z. Parris
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Nature Portfolio 2024-08-01
Σειρά:	Scientific Reports
Θέματα:	Transcriptomic signature Molecular docking Drug screening Drug discovery Drug mechanism-of-action Antineoplastic agents
Διαθέσιμο Online:	https://doi.org/10.1038/s41598-024-69465-6
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!